Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer
1998

Increased serum p53 antibody levels indicate poor prognosis in colorectal cancer

Sample size: 184 publication Evidence: moderate

Author Information

Author(s): U Kressner, B Glimelius, R Bergstrom, L Pahiman, A Larsson, G Lindmark

Primary Institution: University Hospital, Uppsala

Hypothesis

Are serum p53 antibody levels associated with tumor stage and patient survival in colorectal cancer?

Conclusion

Increased serum p53 antibody levels are associated with poorer prognosis in colorectal cancer patients.

Supporting Evidence

  • 32% of patients had increased levels of p53 antibodies.
  • Patients with increased p53 antibodies had shorter survival times.
  • The study found a significant relationship between p53 antibody status and cancer-specific survival time.
  • Serum p53 antibody levels increased with more advanced Dukes' stage.

Takeaway

If a patient has high levels of a certain antibody in their blood, it might mean their cancer is more aggressive and they might not live as long.

Methodology

Serum samples were analyzed using an enzyme-linked immunosorbent assay (ELISA) to measure p53 antibody levels before surgery.

Limitations

The prognostic value of p53 antibody levels diminished when adjusted for Dukes' stage in multivariate analysis.

Participant Demographics

Patients were resected for colorectal cancer, with a median follow-up of 6 years.

Statistical Information

P-Value

P = 0.03

Confidence Interval

95% CI 0.78-3.07

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication